Paper36735698
Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection.
Qiao Y and 15 others. PLoS One, 2023. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. Papers, record 36735698. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36735698
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| SARS-CoV-2 | Major topic |
| COVID-19 | Major topic |
| Humans | |
| Angiotensin-Converting Enzyme 2 | |
| Oligonucleotides, Antisense | |
| Pandemics | |
| Peptidyl-Dipeptidase A | |
| Virus Internalization |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 DK120623 | NIDDK NIH HHS | United States | R01DK120623 | PubMed and NIH | NIH RePORTER |
| Howard Hughes Medical Institute | United States | PubMed | PubMed |
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34614327 | Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34614327 | PubMed |
| 2 | 34373623 | Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. | Nat Rev Immunol | 2021 | https://conductscience.org/library/papers/34373623 | PubMed |
| 3 | 35221061 | Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern. | J Dairy Sci | 2022 | https://conductscience.org/library/papers/35221061 | PubMed |
| 4 | 34120909 | Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. | J Neuromuscul Dis | 2021 | https://conductscience.org/library/papers/34120909 | PubMed |
| 5 | 34535792 | The biological and clinical significance of emerging SARS-CoV-2 variants. | Nat Rev Genet | 2021 | https://conductscience.org/library/papers/34535792 | PubMed |
| 6 | 32225175 | Structural basis of receptor recognition by SARS-CoV-2. | Nature | 2020 | https://conductscience.org/library/papers/32225175 | PubMed |
| 7 | 34471255 | Cellular host factors for SARS-CoV-2 infection. | Nat Microbiol | 2021 | https://conductscience.org/library/papers/34471255 | PubMed |
| 8 | 16700890 | Antisense oligonucleotides: from design to therapeutic application. | Clin Exp Pharmacol Physiol | 2006 | https://conductscience.org/library/papers/16700890 | PubMed |
| 9 | 34611326 | Mechanisms of SARS-CoV-2 entry into cells. | Nat Rev Mol Cell Biol | 2022 | https://conductscience.org/library/papers/34611326 | PubMed |
| 10 | 32445440 | Remdesivir for the Treatment of Covid-19 - Final Report. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32445440 | PubMed |
| 11 | 33353982 | Gene regulation by long non-coding RNAs and its biological functions. | Nat Rev Mol Cell Biol | 2021 | https://conductscience.org/library/papers/33353982 | PubMed |
| 12 | 29443664 | Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29443664 | PubMed |
| 13 | 25614280 | Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. | Arterioscler Thromb Vasc Biol | 2015 | https://conductscience.org/library/papers/25614280 | PubMed |
| 14 | 33882225 | Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33882225 | PubMed |
| 15 | 34381216 | Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. | Nat Struct Mol Biol | 2021 | https://conductscience.org/library/papers/34381216 | PubMed |
| 16 | 22614180 | Structure and nuclease resistance of 2',4'-constrained 2'-O-methoxyethyl (cMOE) and 2'-O-ethyl (cEt) modified DNAs. | Chem Commun (Camb) | 2012 | https://conductscience.org/library/papers/22614180 | PubMed |
| 17 | 18258313 | Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. | Antiviral Res | 2008 | https://conductscience.org/library/papers/18258313 | PubMed |
| 18 | 34614326 | Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34614326 | PubMed |
| 19 | 33600796 | Antisense technology: A review. | J Biol Chem | 2021 | https://conductscience.org/library/papers/33600796 | PubMed |
| 20 | 34278671 | Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation*. | Angew Chem Int Ed Engl | 2021 | https://conductscience.org/library/papers/34278671 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42890159 | Structural insights into an aptainhibitor of the SARS-CoV-2 E protein using molecular docking, molecular dynamics, and biophysical analyses. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42890159 | PubMed |
| 41580734 | The silent epidemic within the pandemic: pathophysiology and prediction of post-COVID-19 diabetes. | J Transl Med | 2026 | https://conductscience.org/library/papers/41580734 | PubMed |
| 41226561 | Application of Antisense Oligonucleotides as an Alternative Approach for Gene Expression Control and Functional Studies. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41226561 | PubMed |
| 40723836 | Endogenous Ribonucleases: Therapeutic Targeting of the Transcriptome Through Oligonucleotide-Triggered RNA Inactivation. | Biomolecules | 2025 | https://conductscience.org/library/papers/40723836 | PubMed |
| 40686860 | Antisense oligonucleotides targeting the SARS-CoV-2 nucleocapsid gene decrease viral titers in hamsters. | Mol Ther Nucleic Acids | 2025 | https://conductscience.org/library/papers/40686860 | PubMed |
| 39947217 | Targeting the SARS-CoV-2 reservoir in long COVID. | Lancet Infect Dis | 2025 | https://conductscience.org/library/papers/39947217 | PubMed |
| 39630134 | Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibition. | RNA Biol | 2024 | https://conductscience.org/library/papers/39630134 | PubMed |
| 39599817 | Viral RNA Interactome: The Ultimate Researcher's Guide to RNA-Protein Interactions. | Viruses | 2024 | https://conductscience.org/library/papers/39599817 | PubMed |
| 38914784 | Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. | BioDrugs | 2024 | https://conductscience.org/library/papers/38914784 | PubMed |
| 37626929 | Antisense Therapy for Infectious Diseases. | Cells | 2023 | https://conductscience.org/library/papers/37626929 | PubMed |
| 37459541 | Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response. | Proc Natl Acad Sci U S A | 2023 | https://conductscience.org/library/papers/37459541 | PubMed |
| 37318607 | Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2. | Top Curr Chem (Cham) | 2023 | https://conductscience.org/library/papers/37318607 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACE2 | 59272 | PubTator's text mining | https://conductscience.org/library/genes/59272 | NCBI Gene |
| AR | 367 | PubTator's text mining | https://conductscience.org/library/genes/367 | NCBI Gene |
| DMD | 1756 | PubTator's text mining | https://conductscience.org/library/genes/1756 | NCBI Gene |
| DNER | 92737 | PubTator's text mining | https://conductscience.org/library/genes/92737 | NCBI Gene |
| EZH2 | 2146 | PubTator's text mining | https://conductscience.org/library/genes/2146 | NCBI Gene |
| GAPDH | 2597 | PubTator's text mining | https://conductscience.org/library/genes/2597 | NCBI Gene |
| RNASEH1 | 246243 | PubTator's text mining | https://conductscience.org/library/genes/246243 | NCBI Gene |
| RNASEL | 6041 | PubTator's text mining | https://conductscience.org/library/genes/6041 | NCBI Gene |
| TMPRSS2 | 7113 | PubTator's text mining | https://conductscience.org/library/genes/7113 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36735698
GET https://conductscience.org/api/papers/v1/36735698/references?page=2